Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Nimbus will ⁠use its ⁠AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

Privately-held Boston, USA-based Nimbus Therapeutics today announced it has entered into a multi-year research collaboration ...

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it ...

Shares of Alumis Inc. (NASDAQ:ALMS) were selling for $16.93, up $8.62, or 103%, having traded as high as $22.30 on positive top-line results from the phase III Onward1 and Onward2 trials with ...

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators. Please wait a minute before you try to comment again.

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...